Journal of Pediatric Urology
Volume 5, Issue 1 , Pages 13-16 , February 2009

The molecular pathways behind bladder stretch injury

Received 8 May 2008 ,Accepted 5 August 2008.

References 

  1. Levin RM, Monson FC, Haugaard N, Buttyan R, Hudson A, Roelofs M, et al. Genetic and cellular characteristics of bladder outlet obstruction. Urol Clin North Am. 1995 May;22(2):263–283
  2. Close CE. Urethral valves and potential for healing in very young patients. Am Urol Assoc Update Series. 2000;19:106–111
  3. Jaureguizar E, Lopez-Pereira P, Martinez-Urratia MJ. The valve bladder: etiology and outcome. Curr Urol Rep. 2002;3:115–120
  4. Dik P, Klijn AJ, van Gool JD, de Jong-de Vos van Steenwijk CC, de Jong TP. Early start to therapy preserves kidney function in spina bifida patients. Eur Urol. 2006 May;49(5):908–913
  5. Bolduc S, Upadhyay J, Payton J, Bagli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure. BJU Int. 2003 March;91(4):398–401
  6. Metcalfe PD, Rink RC. Bladder augmentation: complications in the pediatric population. Curr Urol Rep. 2007 March;8(2):152–156
  7. Ingber DE. Mechanobiology and diseases of mechanotransduction. Ann Med. 2003;35(8):564–577
  8. Bagli DJ, Joyner BD, Mahoney SR, McCulloch L. The hyaluronic acid receptor RHAMM is induced by stretch injury of rat bladder in vivo and influences smooth muscle cell contraction in vitro. J Urol. 1999 September;162(3 Pt 1):832–840
  9. Capolicchio G, Aitken KJ, Gu JX, Reddy P, Bagli DJ. Extracellular matrix gene responses in a novel ex vivo model of bladder stretch injury. J Urol. 2001 June;165(6 Pt 2):2235–2240
  10. Bagli DJ, Van Savage JG, Khoury AE, Carr M, McLorie GA. Basic fibroblast growth factor in the urine of children with voiding pathology. J Urol. 1997 September;158(3 Pt 2):1123–1127
  11. Estrada CR, Adam RM, Eaton SH, Bagli DJ, Freeman MR. Inhibition of EGFR signaling abrogates smooth muscle proliferation resulting from sustained distension of the urinary bladder. Lab Invest. 2006 December;86(12):1293–1302
  12. Herz DB, Aitken K, Bagli DJ. Collagen directly stimulates bladder smooth muscle cell growth in vitro: regulation by extracellular regulated mitogen activated protein kinase. J Urol. 2003 November;170(5):2072–2076
  13. Halachmi S, Aitken KJ, Szybowska M, Sabha N, Dessouki S, Lorenzo A, et al. Role of signal transducer and activator of transcription 3 (STAT3) in stretch injury to bladder smooth muscle cells. Cell Tissue Res. 2006 October;326(1):149–158
  14. Aitken KJ, Block G, Lorenzo A, Herz D, Sabha N, Dessouki O, et al. Mechanotransduction of extracellular signal-regulated kinases 1 and 2 mitogen-activated protein kinase activity in smooth muscle is dependent on the extracellular matrix and regulated by matrix metalloproteinases. Am J Pathol. 2006 August;169(2):459–470
  15. Dozmorov MG, Kropp BP, Hurst RE, Cheng EY, Lin HK. Differentially expressed gene networks in cultured smooth muscle cells from normal and neuropathic bladder. J Smooth Muscle Res. 2007 April;43(2):55–72
  16. Adam RM, Eaton SH, Estrada C, Nimgaonkar A, Shih SC, Smith LE, et al. Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells. Physiol Genomics. 2004 December 15;20(1):36–44
  17. Hipp J, Andersson KE, Kwon TG, Kwak EK, Yoo J, Atala A. Microarray analysis of exstrophic human bladder smooth muscle. BJU Int. 2008 January;101(1):100–105
  18. Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int. 2008 March 11;
  19. de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol. 2008 March 19;
  20. Mitrofanoff P. Trans-appendicular continent cystostomy in the management of the neurogenic bladder. Chir Pediatr. 1980;21(4):297–305
  21. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet. 2006 April 15;367(9518):1241–1246
  22. Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004 September;54(Suppl. 1):S32–S39
  23. Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park). 2006 April;20(5 Suppl. 2):15–25

PII: S1477-5131(08)00357-4

doi: 10.1016/j.jpurol.2008.08.003

Journal of Pediatric Urology
Volume 5, Issue 1 , Pages 13-16 , February 2009

Article Tools